title: [Chronic eosinophilic pneumonia complicated by bronchial asthma and diabetes mellitus successfully treated with suplatast tosilate and high-dose inhaled corticosteroid therapy].
abstract: A 54-year-old woman complained of dyspnea, cough, and productive sputum. Auscultation detected a wheeze in the left and right lung fields. Chest x-ray and computed tomographic films showed non-segmental infiltration in the left upper lung field. Laboratory data revealed eosinophilia in peripheral blood and sputum, elevated levels of serum interleukin-5 (IL-5), airflow limitation, hypoxemia, and heightened airway sensitivity to methacholine (D min : 0.42 units). Bronchoalveolar lavage disclosed an increase in the total number of cells, a 32% increase in eosinophils, and a decreased CD 4/CD 8 ratio of 0.7. Transbronchial lung biopsy specimens revealed infiltrations of eosinophils in the alveolar and interstitial compartments. The histologic features of bronchial biopsy specimens included increased eosinophils in the submucosa and squamous metaplasia. In addition, blood glucose and HbA 1 c levels were elevated. Chronic eosinophilic pneumonia complicated by bronchial asthma and diabetes mellitus was diagnosed. Because the patient was diabetic, she was given suplatast tosilate to reduce the production of IL-5, and high-dose inhaled corticosteroid (beclometasone dipropionate, 1,600 mcg/day) instead of oral corticosteroid therapy. Her symptoms were relieved, peak expiratory flow rates increased, serum IL-5 levels became undetectable, airway sensitivity to methacholine decreased (D min : 4.64 units), and the radiographic abnormalities disappeared. Furthermore, treatment with beclomethasone dipropionate was progressively reduced to 1,200 mcg/day over the subsequent year without relapse. It was concluded that suplatast tosilate and high-dose inhaled corticosteroid therapy may be an effective alternative therapeutic approach to chronic eosinophilic pneumonia in some cases.
authors.affiliation: Department of Internal Medicine, Niigata Prefectural Shibata Hospital, Ohte-cho 4-5-48, Shibata 957-8588, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fujimori
authors.forename: Y
authors.initials: Y
authors.lastname: Shimatsu
authors.forename: E
authors.initials: E
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Arakawa
authors.forename: F
authors.initials: F
authors.lastname: Gejyo
mesh_terms: D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001190:Arylsulfonates / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications*; D001507:Beclomethasone / Q000008:administration & dosage*; D002908:Chronic Disease; D048909:Diabetes Complications; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D008875:Middle Aged; D011657:Pulmonary Eosinophilia / Q000150:complications* / Q000188:drug therapy*; D013452:Sulfonium Compounds / Q000627:therapeutic use*
chemical_list: D018927:Anti-Asthmatic Agents; D001190:Arylsulfonates; D015848:Interleukin-5; D013452:Sulfonium Compounds; C073028:suplatast tosilate; D001507:Beclomethasone